CSL Limited (CSL.AX)
| Previous Close | 278.45 |
| Open | 275.10 |
| Bid | 293.53 x 13700 |
| Ask | 273.61 x 21700 |
| Day's Range | 272.37 - 275.24 |
| 52 Week Range | 228.65 - 312.99 |
| Volume | |
| Avg. Volume | 724,103 |
| Market Cap | 132.073B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 34.86 |
| EPS (TTM) | 7.84 |
| Earnings Date | Feb 13, 2024 |
| Forward Dividend & Yield | 3.81 (1.39%) |
| Ex-Dividend Date | Mar 11, 2024 |
| 1y Target Est | 303.66 |
GlobeNewswireTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Simply Wall St.CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...
